Table 3 Summary of deepening responses among patients with a response of very good partial response (VGPR) or partial response (PR) at study entry, as assessed by the independent review committee, according to minimal residual disease (MRD) status at study entry.

From: Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

 

MRD-negative

N = 124a

n (%)

MRD-positive

N = 293a

n (%)

Relative risk (95%CI)

P value

VGPR at study entry

109 (88)

206 (70)

  

 Deepened to CR

66 (61)

54 (26)

2.310 (1.755, 3.040)

–

PR at study entry

15 (12)

87 (30)

  

  Deepened to VGPR or better

12 (80)

40 (46)

1.740 (1.238, 2.446)

 

VGPR or PR at study entry

124 (100)

293 (100)

 

–

  Deepening response

78 (63)

94 (32)

2.066 (1.668, 2.558)

<0.001

  1. P value determined using a Cochran–Mantel–Haenszel test stratified by response at study entry.
  2. CI confidence interval, CR complete response, MRD minimal residual disease, PR partial response, VGPR very good partial response.
  3. aMRD status at study entry was evaluable in 357 and 228 patients in the ixazomib and placebo arms, respectively; 117 (33%) and 75 (33%), respectively, were MRD-negative, of whom 124 overall had a response of VGPR or PR at study entry; 225 (63%) and 139 (61%), respectively, were MRD-positive, of whom 293 overall had a response of VGPR or PR at study entry. MRD status was evaluated by eight-color flow cytometry with a sensitivity of 10−5.
Back to article page